The vaccine approval is real. Australia's veterinary medicine regulator approved the world's first vaccine to protect koalas from chlamydia, the leading cause of death in koalas in Queensland and NSW, under the APVMA's minor use category . The Australian Environment Minister confirmed the vaccine "has now been registered by the Australian Pesticides and Veterinary Medicines Authority," describing it as "a decade in the making."

The disease burden is well documented. Official NSW government guidance states that in severe cases chlamydiosis causes disease of the eye, urinary tract and reproductive tract, with keratoconjunctivitis causing swelling and inflammation of the eye and surrounding tissue , and this "can cause discharge and, in severe cases, lead to blindness," while reproductive tract infections also occur .

The 50 percent figure traces to a researcher's characterisation, not a national survey. The number originates with the vaccine's developer: "Some individual colonies are edging closer to local extinction every day, particularly in South East Queensland and New South Wales, where infection rates within populations are often around 50 percent and in some cases can reach as high as 70 percent," said Peter Timms . National Geographic's own article reproduces this: "In many populations of the beloved marsupial, around 50 percent are infected; in the hardest hit groups, it's as much as 70 percent. The disease can lead to bladder inflammation, infertility, blindness, and starvation, and causes up to half the koala deaths in the wild."

Peer-reviewed prevalence data show enormous variation, not a uniform 50 percent. A Queensland field study found 31% of 160 koalas in a peri-urban wild population were Chlamydia PCR positive and 28% had clinically detectable chlamydial disease . In South Australia, researchers found 46.7% of surveyed Mount Lofty Ranges koalas positive by PCR, but clinical disease in only 4% of koalas . In Victoria, Chlamydia pecorum was detected in two populations at 25% and 41% prevalence, and was not detected at all in a third population . Australia's national wildlife health body reports the range as varying widely between wild populations, from 0 per cent to nearly 90 per cent .

METHODOLOGY AND CONTEXT

The underlying vaccine study. The npj Vaccines paper is a 10-year retrospective assessment of a Major Outer Membrane Protein (MOMP)-based vaccine's effectiveness against chlamydial disease . Results showed vaccinated koalas had significantly lower disease incidence, with a 64% reduction in chlamydial mortality.

The field work involved 680 koalas in one wild population over 10 years, demonstrating that vaccinated animals had lower incidence of clinical disease and reduced infection-associated mortality, representing real-world evidence that cannot be captured in controlled laboratory models.

Important design limitation. This was a retrospective pooled analysis of five earlier trials, not a single randomised controlled trial. The authors themselves flag the constraint: "For each of the individual trials there was a vaccine efficacy difference of more than 76% (between 16.64% and 93.14% effective), however, due to the limited numbers of animals in each trial this analysis is limited." That confidence interval is very wide.

A correction was issued. An Author Correction published in npj Vaccines states that in the original article the number of vaccinated koalas was incorrectly reported as 165 and should have been 163, with Table 2 and corresponding Results text updated. UniSC has publicly acknowledged this: "Since publication we have found minor errors in the data and these have been acknowledged and corrected, and the journal informed of this. We have recently taken a conservative approach and removed some data points and reanalysed the data. Our preliminary analysis using this new approach still shows a significant difference between vaccinated and unvaccinated koalas in reducing the development of disease."

The regulatory status is more provisional than "approved" suggests. Australia authorised the koala Chlamydia pecorum vaccine under an APVMA Minor Use Permit (PER94984), allowing supervised deployment while efficacy assessment continues . This permit provides "time-limited authorisation for a low-volume, species-specific product that would not generate sufficient economic return to justify full registration." Critically: "the APVMA permit explicitly states that the product is not a registered vaccine and that efficacy has not been fully evaluated." UniSC confirms the process is ongoing: "The APVMA approved a Minor Use Permit on the basis of their initial assessment."

Not all koala chlamydia vaccines have worked. An independent trial of a different MOMP formulation found the opposite result: in a randomised 18-month wild koala trial, "Vaccination did not alter clinical disease expression or chlamydial shedding from the ocular or urogenital sites" and "did not stimulate a significant plasma anti-MOMP IgG response, when compared to the placebo group." This was a synthetic peptide vaccine, distinct from the approved UniSC product, but it demonstrates that MOMP-based approaches are not automatically effective.